View Older Stories

Apr 29, 2026 08:05AM enVVeno Medical Receives First-Ever FDA IDE Approval for a U.S. Pivotal Study of a Non-Surgical Replacement Venous Valve

Mar 27, 2026 08:30AM enVVeno Medical Reports Full Year 2025 Financial Results and Highlights Strategic Advancement of enVVe(R) System

Feb 4, 2026 08:31AM enVVeno Medical regains Nasdaq compliance with $1 bid requirement

Feb 4, 2026 08:30AM enVVeno Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jan 15, 2026 08:01AM enVVeno Medical completes 1-for-35 reverse stock split

Jan 15, 2026 08:00AM enVVeno Medical Announces Reverse Stock Split

Nov 26, 2025 08:48AM enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 13, 2025 05:00PM enVVeno receives unfavorable FDA appeal decision for VenoValve device

Nov 13, 2025 05:00PM enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Nov 13, 2025 04:55PM enVVeno Medical (NVNO) Halted, News Pending

Oct 31, 2025 08:05AM enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025 08:45AM enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025 08:47AM enVVeno Medical to appeal FDA rejection of VenoValve device

Sep 15, 2025 08:45AM enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 21, 2025 06:52AM Ladenburg Thalmann Downgrades enVVeno Medical Corp (NVNO) to Neutral

Aug 20, 2025 07:00AM enVVeno receives FDA rejection for VenoValve medical device

Aug 20, 2025 07:00AM enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 20, 2025 06:57AM enVVeno Medical (NVNO) Halted, News Pending

Aug 15, 2025 09:21AM enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025 08:32AM enVVeno Medical study shows VenoValve could save $32,442 per patient

Aug 6, 2025 08:30AM Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025 09:05AM enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025 08:00AM enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025 08:45AM enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference

Jul 22, 2025 08:40AM JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Jun 6, 2025 08:05AM Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025 08:10AM enVVeno Medical (NVNO) hires Jennifer Bright as CFO

May 19, 2025 08:05AM enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025 08:45AM Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025 08:05AM enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025 08:00AM VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025 08:30AM enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025 09:00AM The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Mar 12, 2025 06:35AM enVVeno Medical (NVNO) Files $100M Mixed Shelf

Feb 28, 2025 08:00AM enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025 09:00AM enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025 08:53AM enVVeno Medical (NVNO): One-Year Data from the VenoValve U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life to be Presented Today

Feb 19, 2025 08:45AM One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025 09:01AM enVVeno Medical (NVNO): Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Feb 7, 2025 09:00AM Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024 08:50AM enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024 08:30AM enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024 08:30AM enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024 08:16AM enVVeno Medical (NVNO) Submits the VenoValve PMA Application Seeking FDA Approval

Nov 19, 2024 08:15AM enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Oct 31, 2024 08:35AM enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoVal

Oct 28, 2024 08:30AM enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)

Sep 27, 2024 06:04AM enVVeno Medical (NVNO) Prices 4.3M Share and Warrant Offering at $3.50/sh

Sep 26, 2024 09:18PM enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Sep 26, 2024 04:07PM enVVeno Medical (NVNO) Announces Proposed Share Offering

View Older Stories